TRVI · Trevi Therapeutics, Inc.
$18.46
+0.31 (+1.71%)
At close · Aug 14
Market Cap
$2.63B
Shares
142.48M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $3,944,892 |
| James Cassella | Chief Development Officer | $1,637,220 |
| Farrell Simon | Pharm. D. Chief Commercial Officer | $1,355,897 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $2,589,035 |
| James Cassella | Chief Development Officer | $1,441,119 |
| Lisa Delfini | Chief Financial Officer | $1,187,403 |
| Farrell Simon | Pharm. D. Chief Commercial Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $1,687,298 |
| Thomas Sciascia | Chief Scientific Officer | $977,125 |
| David Clark | M.D., MBChB Chief Medical Officer | $610,638 |
| James Cassella | Chief Development Officer | — |
| Lisa Delfini | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $898,095 |
| David Clark | M.D., MBChB Chief Medical Officer | $580,781 |
| Thomas Sciascia | Chief Scientific Officer | $577,295 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $1,527,439 |
| William Forbes | Pharm. D. Chief Development Officer | $1,180,794 |
| Thomas Sciascia | Chief Scientific Officer | $717,544 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $1,441,457 |
| Yann Mazabraud | Former Chief Commercial Officer and Head of International | $716,856 |
| Chris Seiter | Former Chief Financial Officer | $716,218 |
| Thomas Sciascia | Chief Medical Officer | $709,894 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jennifer Good | President and Chief Executive Officer | $2,810,719 |
| Yann Mazabraud | Former Chief Commercial Officer and Head of International | $914,666 |
| Thomas Sciascia | Chief Medical Officer | $786,845 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Yann Mazabraud | Chief Commercial Officer and Head of International | $1,012,833 |
| Jennifer Good | President and Chief Executive Officer | $528,250 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Hastings | Chief Financial Officer and principal financial officer | Appointed | 2025-12-05 |
| Lisa Delfini | Chief Financial Officer | Resigned | 2025-08-20 |
| Anne VanLent | Class III director | Appointed | 2025-06-17 |
| Jennifer Good | Class III director | Appointed | 2025-06-17 |
| James Cassella, Ph.D. | member of the Board of Directors | Resigned | 2024-10-01 |
| James Cassella, Ph.D. | Chief Development Officer | Appointed | 2024-10-01 |
Key facts
CIK
1563880
CUSIP
89532M101
13F (30d)
213 filings
211 filers
Visit website
Investor relations